Tiger Brokers

Galapagos and Gilead discuss OM336 collaboration with 20%-23% royalties

Reuters
Mar 24
Galapagos and <a href="https://laohu8.com/S/GILD">Gilead</a> discuss OM336 collaboration with 20%-23% royalties
  • Galapagos and Gilead are in advanced discussions on a strategic collaboration related to Ouro Medicines assets, including OM336 (gamgertamig).
  • Proposed terms include Galapagos paying 50% of the USD 1.68 billion upfront consideration and 50% of up to USD 500 million in contingent milestones.
  • The parties would collaborate on development of OM336, with Galapagos covering costs through initiation of registrational studies.
  • Gilead would hold worldwide commercialization rights outside Greater China and would pay Galapagos royalties of 20%-23% of net sales.
  • An amended OLCA is contemplated to allow up to USD 500 million of cash to be used by Galapagos, including up to USD 150 million for potential share repurchases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galapagos NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603231825PRIMZONEFULLFEED1001171777) on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10